Claims for Patent: 8,883,783

Summary for Patent: 8,883,783

Title:	Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith
Abstract:	Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders are disclosed.
Inventor(s):	Shripad S. Bhagwat, Wei Lai, Stephan D. PARENT, Melanie J. Roe, Alan Schwartz, Valeriya N. Smolenskaya
Assignee:	Ambit Bioscience Corp
Application Number:	US12/233,906
Patent Claims:	1. A solid form comprising a salt of the compound of formula (I): wherein the salt is selected from the group consisting of: hydrobromide, besylate, esylate, edisylate, mesylate, napsylate, sulfate and tosylate salts. 2. The solid form of claim 1 which further comprises a solvent. 3. The solid form of claim 1 which further comprises water. 4. A solid form comprising a bis-HCl salt of the compound of formula (I): 5. The solid form of claim 4 which is substantially free of solvent. 6. The solid form of claim 4 which is substantially free of water. 7. The solid form of claim 4 which is anhydrous. 8. The solid form of claim 4 which is the Form B crystal form of the bis-HCl salt of the compound of formula (I). 9. The solid form of claim 4 having an XRPD pattern comprising peaks at approximately 6.98, 10.7, 20.82 and 27.6 ° 2θ when analyzed using copper Kα radiation. 10. The solid form of claim 9 having an XRPD pattern further comprising peaks at approximately 15.78, 18.48, 22.62 and 27.08 ° 2θ when analyzed using copper Kα radiation. 11. The solid form of claim 10 having an XRPD pattern further comprising peaks at approximately 13.04, 18.8, 24.38 and 26.16 ° 2θ when analyzed using copper Kα radiation. 12. The solid form of claim 4 having an XRPD pattern which matches the XRPD patterns presented in FIG. 13 a. 13. The solid form of claim 4 having an XRPD pattern which matches the XRPD pattern presented in FIG. 13 b. 14. The solid form of claim 4 having a DSC thermogram comprising an endothermic event with an onset temperature of approximately 260° C. 15. The solid form of claim 4 having unit cell parameters consistent with the following approximate unit cell parameters: a=15.6089 Å, b=11.9443 Å, c=16.9448 Å, β=101.249°, V=3098.5 Å3 and Z=4. 16. The solid form of claim 4 which is physically stable at about 75% RH at about ambient temperature. 17. The solid form of any of claim 5, 6, 7 or 8 which is substantially pure. 18. The solid form of claim 5, 6, 7 or 8 which is substantially free of chemical impurities. 19. The solid form of claim 5, 6, 7 or 8 which is substantially free of physical impurities. 20. A pharmaceutical composition comprising the solid form of any of claim 5, 6, 7 or 8. 21. An amorphous form comprising the compound of the following formula, or a pharmaceutically acceptable salt thereof: 22. A crystal form comprising the compound of the following formula: which is selected from the group consisting of: a. Form A of the HCl salt; b. Form B of the HCl salt; c. Form C of the HCl salt, d. Form D of the HCl salt; e. Form E of the HCl salt; f. Form F of the HCl salt; g. Form G of the HCl salt; h. Form H of the HCl salt; i. Form I of the HCl salt; j. Form J of the HCl salt; k. Form K of the HCl salt; l. Form L of the HCl salt; m. Form N of the HCl salt; n. Form O of the HCl salt; o. Form A of the HBr salt; P. Form A of the sulfate salt; q. Form B of the sulfate salt; r. Form C of the sulfate salt; s. Form A of the mesylate salt; t. Form B of the mesylate salt; u. Form A of the esylate salt; v. Form B of the esylate salt; w. Form C of the esylate salt; x. Form A of the edisylate salt; y. Form A of the besylate salt; z. Form B of the besylate salt; aa. Form A of the tosylate salt; bb. Form B of the tosylate salt; cc. Form C of the tosylate salt; dd. Form A of the napsylate salt; and ee. Form B of the napsylate salt. 23. A pharmaceutical composition comprising the crystal form of claim 22.